5 December 2025
Resolution to increase the share capital in connection with settlement of underwriting fee
5 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue of 260,000,000 new shares in the Company (the “Offer Shares”) raising gross proceeds of NOK 130 million (the “Rights Issue”).
In connection with the Rights Issue, a total of 31,199,997 new shares, each at a subscription price of NOK 0.50 (the “Underwriting Commission Shares”) shall be delivered to the underwriters pursuant to the subscription and underwriting agreements dated 30 June 2025 as settlement of their entitlement to underwriting fee under said agreements.
In accordance with the authorisation granted to the board of directors at the extraordinary general meeting held on 4 August 2025, the board of directors has today resolved to increase the share capital of the Company by NOK 15,599,998.50 by the issuance of 31,199,997 new shares, each with a nominal value of NOK 0.5 and a subscription price of NOK 0.50. The subscription price of NOK 0.50 per Underwriting Commission Share is equal to the subscription price in the Rights Issue.
The share capital increase relating to the issuance of the Underwriting Commission Shares is expected to be registered with the Norwegian Register of Business Enterprises on or about 9 December 2025, and the Underwriting Commission Shares are expected to be delivered to the underwriters on or about 10 December 2025.
For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com
This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases in the peritoneum post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. One Phase 1 trial and one Phase 1/2a trial have been completed and one randomized Phase 2 trial in ovarian cancer is currently ongoing in the US and Europe. Early clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. Oncoinvent runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo Stock Exchange.
About Radspherin®
Radspherin® is an innovative internal radiation therapy designed to directly target microscopic metastases in the abdominal cavity following surgery. Radspherin® is currently in development as a post-surgical treatment for patients with cancer that has spread to the abdominal cavity – a group with very limited treatment options today. The drug candidate offers a distinctly unique therapeutic approach with several differentiating features, including the use of radium-224, single-dose treatment with a sustained therapeutic effect, non-systemic administration, direct targeting and an exceptional dose-to-tumor ratio, maximizing efficacy while limiting harm to healthy tissue
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
